Evogene (NASDAQ:EVGN) Releases Earnings Results, Beats Expectations By $0.78 EPS

Evogene (NASDAQ:EVGN) posted its earnings results on Thursday. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.78, Zacks reports. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. During the same period in the previous year, the firm earned ($1.30) EPS.

Evogene Stock Up 1.4 %

Shares of EVGN traded up $0.02 during trading hours on Thursday, reaching $1.43. 27,796 shares of the company traded hands, compared to its average volume of 89,101. Evogene has a 12 month low of $1.20 and a 12 month high of $10.00. The company has a market capitalization of $7.69 million, a price-to-earnings ratio of -0.32 and a beta of 1.29. The company’s fifty day moving average price is $1.59 and its two-hundred day moving average price is $2.09.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Evogene in a research report on Sunday. They issued a “sell” rating on the stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.